Work

Early Vericiguat Initiation After First Hospitalization for Heart Failure With Reduced Ejection Fraction ― A Multicenter Observational Study From the VERIFY-HF Registry and Institutional Cohorts ―

Year: 2026
Type: article
Study design: Observational Study
Abstract: Background: Hospitalization for the first episode of heart failure with reduced ejection fraction (HFrEF) represents an important opportunity to initiate evidence-based therapies. In this study, we aimed to clarify the role of vericiguat after first hospitalization for HFrEF in routine clinical practice. Methods and Results: This multicenter retrospective cohort study included patients with HFrEF at their first hospitalization between June 2021 and September 2023 identified from the nationwide Verifying Characteristics and Outcomes in Heart Failure Patients Treated with Vericiguat registry (vericiguat group, n=104) and 2 institutional databases (control group, n=206) (mean age, 67 years; 71% male). The primary endpoint was a composite of cardiovascular death or HF rehospitalization within 1 year. In inverse probability of treatment weighting-adjusted Cox models, vericiguat use was associated with a lower risk of the primary endpoint, compared with controls (hazard ratio, 0.26; 95% confidence interval, 0.08-0.81). Sensitivity analysis using alternative weighting methods and a doubly robust model yielded consistent results. Conclusions: In this real-world Japanese cohort of patients at first hospitalization for HFrEF, vericiguat initiation during index hospitalization was associated with a lower risk of cardiovascular death or HF rehospitalization after discharge. The observed association was directionally consistent with previous trials and pooled analyses, suggesting a potential benefit for this intermediate real-world population.
Language: English
Field: Medicine
Open Access status: diamond
OpenAlex ID: W7214317398
FWCI:
Cites: 21
Cited by:
Related to: 10